Lifecore Biomedical (LFCR) Q2 FY26 earnings call

Lifecore Biomedical reported a mixed Q2 FY26, with revenue and adjusted EBITDA declines, but reaffirmed its full-year guidance, citing strong business development momentum and a robust pipeline. The company successfully navigated numerous audits and added 6 new programs, including late-stage and commercial site transfers. Management highlighted significant SG&A reductions and improved liquidity, positioning the company for anticipated demand increases from its largest customer starting in 2027.